Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment
Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment
Continuous therapy in multiple myeloma; updates from MM4 and MM6 including China perspective
First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation
Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma
Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin lymphoma real world evidence data
Five year update of ECHELON-1 for classical Hodgkin lymphoma
Blinatumomab and oral TKIs for the treatment of Ph ALL
D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph ALL
Real world management of multiple myeloma patients
Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-year results
Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients
Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study